BioLab Fluid GF™ is an amniotic liquid allograft derived from the amniotic fluid within the amniotic sac used to protect, lubricate and cushion.

The safety and quality of Fluid GF™ is carefully controlled. Fluid GF™ liquid allograft is processed following stringent FDA regulations and requirements.
Amniotic liquid is abundant in growth factors and cytokines associated with repair, replacement, and regeneration of soft tissue. When injected into the body, these growth factors and cytokines have been shown to promote healing and pain management.
Fluid GF™ was issued Q-Code: Q4206 by CMS for soft tissue pain and inflammation and therefore can be reimbursed by Medicare making this an affordable option for your patients.

Partnering for PATIENT and PRACTICE Success

We specialize in integrating amniotic solutions into your practice by working with your team to provide product and billing support, as well as the tools to educate and inform your patients.
As you prepare to offer this solution to your patients, we work with your team to provide training and documentation on the product, the procedure, and patient communication.
We provide training and support for your billing team to submit reimbursement for Medicare and other insurance providers. We provide Insurance Verification services as well as a reimbursement guarantee.
We provide educational materials and tools to support your patient education efforts, always ensuring your patients have the knowledge they need to make an informed decision.


The medial literature has demonstrated over the last 100 years that using placental allografts promotes healing of many conditions.

Studies of amniotic liquid use, as well as journal articles regarding use are available in the public domain. Note all of these articles and clinical trials are done on pure amniotic liquid, however, the patient outcomes derived from the growth factors, cytokines, and proteins contained in the amniotic products may be similar.

Amniotic Fluid May be a Safe and Effective Alternative to Hyaluronic Acid for Osteoarthritis Pain: Interim Results

An Amniotic fluid based injection in this study offered pain and functional improvement that was greater at 13 weeks than at 30 days and appears to offer long-lasting relief at higher levels.

Results observed in the first 170 amniotic fluid-treated patients showed their VAS and WOMAC scores improved an average of 68.1% (44mm) and 70.9% (812mm) respectively, at 30 days. Improvements increased at 90 days to 82% for WOMAC and 74% for VAS.

Study Shows Positive Clinical Outcomes: Amniotic Fluid for Osteoarthritis

In the study, results after a knee injection of amniotic fluid showed longer lasting results and a decrease of pain each month. The study stated, “amniotic fluid injection present an excellent, safe, and longer lasting alternative for treating osteoarthritis due to its cushioning effect similar to hyaluronic acid and its anti-inflammatory and regenerative components.

Clinical Study: Amniotic Fluid for Osteoarthritis

This study found that the results of treatment with Amniotic Allograft were superior to Hyaluronic Acid and placebo in this setting. We found significant differences between AA and HA at 3 months, including EQ-5D-5L pain and anxiety subsets; KOOS pain, symptoms, and ADL subsets; and VAS scores for overall pain, pain during strenuous work, and pain during normal daily living.

Article: Amniotic Fluid Allograft

Amniotic fluid donated by healthy donors at the time of C-section has shown much promise in the field of regenerative medicine. In the context of orthopedic surgery, its composition has been shown to have favorable characteristics in decreasing joint inflammation and enhancing the internal environment of the inflamed arthritic joint.

Amniotic fluid contains important cytokines, growth factors, hyaluronic acid, and exosomes that work to promote joint homeostasis and joint lubrication. Exosomes are small vesicles that arise from stem cells and provide a means for tissue repair and joint homeostasis. They provide beneficial signals inherent to the native stem cells, without their direct presence in the regenerative process. Amniotic fluid provides a concentrated mixture of these regenerative components.